Human DBR1 modulates the recycling of snRNPs to affect alternative RNA splicing and contributes to the suppression of cancer development

Oncogene

Volumn 36, Issue 38, 2017, Pages 5382-5391

  Han, B ^a   Park, H K ^b   Ching, T ^a   Panneerselvam, J ^a   Wang, H ^b   Shen, Y ^a   Zhang, J ^b   Li, L ^a,c   Che, R ^a   Garmire, L ^a   Fei, P ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; DEFEROXAMINE; DNA FRAGMENT; ENZYME; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN P53; RNA; RNA DEBRANCHING ENZYME; RNA POLYMERASE II; SMALL NUCLEAR RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; DBR1 PROTEIN, HUMAN; RNA POLYMERASE; TP53 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; EXON SKIPPING; GENE EXPRESSION PROFILING; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA PROCESSING; SEQUENCE ANALYSIS; SPLICING DEFECT; TRANSCRIPTOMICS; BIOSYNTHESIS; CELL HYPOXIA; ENZYMOLOGY; EXON; GENETICS; INTRON; METABOLISM; NEOPLASM; PHYSIOLOGY; RNA SPLICING; TUMOR CELL LINE;

ALTERNATIVE SPLICING; CELL HYPOXIA; CELL LINE, TUMOR; EXONS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INTRONS; NEOPLASMS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; RNA NUCLEOTIDYLTRANSFERASES; RNA SPLICING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85031666062     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2017.150     Document Type: Article

References (52)

1. Bischof O, Martinez-Zamudio RI. MicroRNAs and lncRNAs in senescence: a re-view. IUBMB Life 2015; 67: 255-267.
2. Frye M, Blanco S. Post-transcriptional modifications in development and stem cells. Development 2016; 143: 3871-3881.
3. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010; 463: 457-463.
4. Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell Biol 2014; 15: 108-121.
5. Carstens RP. Networking in an alternative splicing world. Mol Cell 2014; 54: 903-904.
6. Ruskin B, Green MR. An RNA processing activity that debranches RNA lariats. Science 1985; 229: 135-140.
7. Clark NE, Katolik A, Roberts KM, Taylor AB, Holloway SP, Schuermann JP et al. Metal dependence and branched RNA cocrystal structures of the RNA lariat debranching enzyme Dbr1. Proc Natl Acad Sci USA 2016; 113: 14727-14732.
8. Kataoka N, Dobashi I, Hagiwara M, Ohno M. hDbr1 is a nucleocytoplasmic shuttling protein with a protein phosphatase-like motif essential for debranching activity. Sci Rep 2013; 3: 1090.
9. Li Z, Wang S, Cheng J, Su C, Zhong S, Liu Q et al. Intron Lariat RNA Inhibits MicroRNA Biogenesis by Sequestering the Dicing Complex in Arabidopsis. PLoS Genet 2016; 12: e1006422.
10. Zheng S, Vuong BQ, Vaidyanathan B, Lin JY, Huang FT, Chaudhuri J. Non-coding RNA generated following lariat debranching mediates targeting of AID to DNA. Cell 2015; 161: 762-773.
11. Sharp PA, Eisenberg D. The evolution of catalytic function. Science 1987; 238: 729-730 807.
12. Barrett SP, Wang PL, Salzman J. Circular RNA biogenesis can proceed through an exon-containing lariat precursor. Elife 2015; 4: e07540.
13. Hube F, Ulveling D, Sureau A, Forveille S, Francastel C. Short intron-derived ncRNAs. Nucleic Acids Res 2017; 45: 4768-4781.
14. Kock KH, Kong KW, Hoon S, Seow Y. Functional VEGFA knockdown with artificial 3'-tailed mirtrons defined by 5' splice site and branch point. Nucleic Acids Res 2015; 43: 6568-6578.
15. Nam K, Lee G, Trambley J, Devine SE, Boeke JD. Severe growth defect in a Schizosaccharomyces pombe mutant defective in intron lariat degradation. Mol Cell Biol 1997; 17: 809-818.
16. Chapman KB, Boeke JD. Isolation and characterization of the gene encoding yeast debranching enzyme. Cell 1991; 65: 483-492.
17. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-2908.
18. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-634.
19. Bitton DA, Rallis C, Jeffares DC, Smith GC, Chen YY, Codlin S et al. LaSSO, a strategy for genome-wide mapping of intronic lariats and branch points using RNA-seq. Genome Res 2014; 24: 1169-1179.
20. Kornblihtt AR, Pesce CG, Alonso CR, Cramer P, Srebrow A, Werbajh S et al. The fibronectin gene as a model for splicing and transcription studies. FASEB J 1996; 10: 248-257.
21. Munoz MJ, Perez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S et al. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009; 137: 708-720.
22. Park HK, Wang H, Zhang J, Datta S, Fei P. Convergence of Rad6/Rad18 and Fanconi anemia tumor suppressor pathways upon DNA damage. PLoS ONE 2010; 5: e13313.
23. Panneerselvam J, Park HK, Zhang J, Dudimah FD, Zhang P, Wang H et al. FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer. Cell Cycle 2012; 11: 2947-2955.
24. Lee Y, Rio DC. Mechanisms and regulation of alternative pre-mRNA splicing. Annu Rev Biochem 2015; 84: 291-323.
25. Kol G, Lev-Maor G, Ast G. Human-mouse comparative analysis reveals that branch-site plasticity contributes to splicing regulation. Hum Mol Genet 2005; 14: 1559-1568.
26. Pastuszak AW, Joachimiak MP, Blanchette M, Rio DC, Brenner SE, Frankel AD. An SF1 affinity model to identify branch point sequences in human introns. Nucleic Acids Res 2011; 39: 2344-2356.
27. Gao K, Masuda A, Matsuura T, Ohno K. Human branch point consensus sequence is yUnAy. Nucleic Acids Res 2008; 36: 2257-2267.
28. Yoshimoto R, Kataoka N, Okawa K, Ohno M. Isolation and characterization of postsplicing lariat-intron complexes. Nucleic Acids Res 2009; 37: 891-902.
29. Kataoka N, Fujita M, Ohno M. Functional association of the microprocessor complex with the spliceosome. Mol Cell Biol 2009; 29: 3243-3254.
30. Azubel M, Wolf SG, Sperling J, Sperling R. Three-dimensional structure of the native spliceosome by cryo-electron microscopy. Mol Cell 2004; 15: 833-839.
31. Ohi MD, Ren L, Wall JS, Gould KL, Walz T. Structural characterization of the fission yeast U5.U2/U6 spliceosome complex. Proc Natl Acad Sci USA 2007; 104: 3195-3200.
32. Fourmann JB, Schmitzova J, Christian H, Urlaub H, Ficner R, Boon KL et al. Dissection of the factor requirements for spliceosome disassembly and the elucidation of its dissociation products using a purified splicing system. Genes Dev 2013; 27: 413-428.
33. Wahl MC, Luhrmann R. SnapShot: spliceosome dynamics I. Cell 2015; 161: 1474-e1471.
34. Chan SP, Kao DI, Tsai WY, Cheng SC. The Prp19p-associated complex in spliceosome activation. Science 2003; 302: 279-282.
35. Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009; 136: 701-718.
36. Ilagan JO, Chalkley RJ, Burlingame AL, Jurica MS. Rearrangements within human spliceosomes captured after exon ligation. RNA 2013; 19: 400-412.
37. Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell 2010; 142: 625-636.
38. Clerte C, Hall KB. The domains of polypyrimidine tract binding protein have distinct RNA structural preferences. Biochemistry 2009; 48: 2063-2074.
39. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell 2016; 29: 452-463.
40. Sullenger BA, Nair S. From the RNA world to the clinic. Science 2016; 352: 1417-1420.
41. Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 2016; 76: 3666-3670.
42. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol 2010; 220: 152-163.
43. Fu D, Dudimah FD, Zhang J, Pickering A, Paneerselvam J, Palrasu M et al. Recruitment of DNA polymerase eta by FANCD2 in the early response to DNA damage. Cell Cycle 2013; 12: 803-809.
44. Fei P, WangW, KimSH, Wang S, Burns TF, Sax JK et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 2004; 6: 597-609.
45. Park HK, Panneerselvam J, Dudimah FD, Dong G, Sebastian S, Zhang J et al. Wip1 contributes to cell homeostasis maintained by the steady-state level of Wtp53. Cell Cycle 2011; 10: 2574-2582.
46. Panneerselvam J, Pickering A, Han B, Li L, Zheng J, Zhang J et al. Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate. Oncotarget 2014; 5: 1326-1337.
47. Panneerselvam J, Pickering A, Zhang J, Wang H, Tian H, Zheng J et al. A hidden role of the inactivated FANCD2: upregulating DeltaNp63. Oncotarget 2013; 4: 1416-1426.
48. Han B, Shen Y, Zhang P, Jayabal P, Che R, Zhang J et al. Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression. Oncotarget 2017; 8: 22490-22500.
49. Panneerselvam J, Xie G, Che R, Su M, Zhang J, Jia W et al. Distinct metabolic signature of human bladder cancer cells carrying an impaired Fanconi anemia tumor-suppressor signaling pathway. J Proteome Res 2016; 15: 1333-1341.
50. Qiu Y, Cai G, Zhou B, Li D, Zhao A, Xie G et al. A distinct metabolic signature of human colorectal cancer with prognostic potential. Clin Cancer Res 2014; 20: 2136-2146.
51. Qiu Y, Zhou B, Su M, Baxter S, Zheng X, Zhao X et al. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int J Mol Sci 2013; 14: 8047-8061.
52. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 2014; 30: 523-530.